T1R2/T1R3 Identified as the Aβ Receptor: A New Mechanism Linking Aβ42/40 Ratio to Neuronal Hyperexcitability in Alzheimer's Disease

Alzheimer's disease is often thought of as a condition defined by memory loss and the slow accumulation of sticky protein clumps in the brain. However, long before a person loses their memory or before those clumps become visible, the brain's electrical activity begins to go haywire. Neurons, the cells that carry electrical signals, start firing too easily and too often. This state of over-activity, known as hyperexcitability, is an early warning sign that appears in patients with mild cognitive impairment. Scientists have long known that a specific chemical signature in the fluid surrounding the brain changes during this early stage. This signature involves the ratio of two very similar proteins, amyloid-beta 42 and amyloid-beta 40. In a healthy brain, there is roughly ten parts of the 40 protein for every one part of the 42 protein. In the early stages of Alzheimer's, this balance shifts, dropping to about ten parts of 40 for every 0.5 part of 42. For years, researchers treated this shift merely as a passive marker, a clue that the disease was present, without understanding if the change itself was actually causing the neurons to misbehave.
A team of researchers has now discovered that this shift in protein ratio is not just a warning light; it is an active switch that turns on the brain's over-activity. They found that the specific mixture of proteins found in Alzheimer's patients acts like a key that fits into a lock on the surface of nerve cells. This lock is a receptor, a protein structure that normally helps the cell taste sweetness, but in the brain, it has a different job. When the researchers applied the Alzheimer's-associated protein mixture to human nerve cells in a dish, the cells immediately began to conduct electricity more strongly. The neurons became more sensitive and fired more readily. In contrast, when they applied the healthy, normal protein mixture, nothing happened. The cells remained calm. This suggests that the change in the ratio of these two proteins is a functional signal that directly drives the electrical chaos seen in early Alzheimer's.
The researchers identified the specific lock on the cell surface that responds to this signal. It is a pair of proteins called T1R2 and T1R3, which usually work together to detect sweet tastes. The study showed that this pair is required for the neurons to react to the Alzheimer's protein mixture. When the researchers blocked or removed either of these two proteins, the neurons stopped responding to the dangerous signal. Interestingly, the third protein in this family, T1R1, was not needed for this process. This discovery reveals that the brain uses a sweet-taste receptor to monitor the balance of amyloid proteins, and when that balance tips toward the disease state, the receptor triggers the neurons to become hyperactive.
One of the most striking aspects of this finding is that it appears to be a uniquely human problem. The researchers tested the same protein mixture on nerve cells of rodent origin, which are commonly used to model Alzheimer's disease in the lab. These rodent cells did not react at all to the Alzheimer's protein mixture, even though they possessed the same sweet-taste receptors. The rodent receptors simply did not recognize the human protein mixture as a signal. However, when the researchers added the human version of the T1R3 protein to the rodent cells, the cells suddenly became sensitive to the mixture and began to over-activate. This explains a long-standing mystery in the field: why many mouse models of Alzheimer's fail to show the early electrical over-activity seen in human patients. The mechanism that drives the disease in humans relies on the human form of a receptor that rodent versions do not recognize.
The study also explored how this process might unfold over time. The researchers suggest that under normal conditions, the brain uses a different signal, a molecule called glutamine, to briefly activate these receptors and strengthen connections between neurons during learning. This is a healthy, short-term boost.
Interestingly, the authors propose that the imbalanced protein mixture plays a role in keeping the receptor switched on in a controlled manner, bridging the short-term boost to the longer-lasting stabilization of learning. In healthy individuals, the balance is restored once the activity subsides.
However, in the early stages of Alzheimer's, the persistent presence of the imbalanced protein mixture keeps the receptor switched on for too long. Instead of a brief spark that helps the brain learn, the signal becomes a constant hum that keeps the neurons firing uncontrollably. This constant firing is what leads to the early symptoms of the disease. The researchers propose that this over-activity is not just a side effect of the disease: in a controlled form it supports memory formation in healthy individuals, and when it persists it may contribute to the hyperexcitability observed in mild cognitive impairment (MCI) and to cognitive decline.
Because this mechanism relies on a specific human protein, it opens up new possibilities for treatment. The researchers suggest that instead of trying to clear all amyloid proteins from the brain, which has been a difficult and often unsuccessful strategy, doctors could target the receptor itself. By blocking the specific way, the Alzheimer's protein mixture binds to the human sweet-taste receptor, it might be possible to stop the neurons from becoming over-active without disrupting the healthy signals the brain needs to function. This approach could potentially calm the electrical storm in the brain during the earliest stages of the disease, offering a way to preserve memory and function before significant damage occurs. The discovery turns a familiar biomarker, once seen only as a sign of trouble, into a clear target for intervention, highlighting a specific molecular pathway that goes wrong in human brains but remains hidden in the animals we have used to study the disease for decades.